Submitted by admin on Mon, 08/24/2015 - 12:00 Source Fierce Pharma Headline Analysts: Gilead's hep C scripts keep slowing, and Q3 sales forecasts should too News Tags Gilead Sovaldi Harvoni hepatitis C